PSNL News and Press, Personalis Inc. From 03/28/24

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be present...

Blood-based assay uses personalized tumor-informed approach designed to detect cancer recurrence early with an ultra-sensitive approach Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company...

2024-03-20 12:25:51 ET More on Mid-day movers & stocks. Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript Personalis Q4 2023 Earnings Preview XTI Aircraft that will merge with Inpixon gets Chinese patent for an aircraft Seeking Alpha’s Quant...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at ...

2024-01-30 09:14:03 ET More on Personalis Personalis forecasts upbeat Q4 revenue outlook Personalis expects workforce reduction to extend cash runway into 2026 Read the full article on Seeking Alpha For further details see: Personalis and ClearNote Health...

Personalis to offer ClearNote’s patented Epigenomic Platform to its biopharmaceutical partners Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health , Inc., a pioneer in epigenomic technologies, today unveiled an alliance through ...

NeXT Dx helps clinicians make informed, personalized cancer treatment selections and match patients with clinical trials Access to NeXT Dx expands to the 66 million Medicare and Medicare Advantage beneficiaries Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for p...

2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...

2024-01-05 09:38:15 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis expects workforce reduction to extend cash runway into 2026 Cancer test developer Personalis to cut 65 jobs to reduce costs Seeking Alpha’s Qu...